Dynavax Hep B vaccine successful in Phase II
There is some good news from the world of drug development today. Dynavax Technologies has revealed positive Phase II results comparing two different vaccination schedules for its hepatitis B vaccine HEPLISAV. The primary endpoint was comparative seroprotection after the second dose, and the trial showed that complete seroprotection is achieved whether the second dose is administered one or two months after the first. Dynavax will be launching a Phase III trial of the vaccine before the end of 2006.
- here's the company press release
Related Article:
Dynavax gains $50M in new research funding. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
